A detailed history of Verdence Capital Advisors LLC transactions in Biogen Inc. stock. As of the latest transaction made, Verdence Capital Advisors LLC holds 1,659 shares of BIIB stock, worth $242,993. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,659
Previous 1,668 0.54%
Holding current value
$242,993
Previous $386,000 16.84%
% of portfolio
0.03%
Previous 0.03%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$189.07 - $236.8 $1,701 - $2,131
-9 Reduced 0.54%
1,659 $321,000
Q2 2024

Jul 25, 2024

BUY
$190.52 - $236.72 $571 - $710
3 Added 0.18%
1,668 $386,000
Q1 2024

Apr 25, 2024

SELL
$212.02 - $267.71 $1,908 - $2,409
-9 Reduced 0.54%
1,665 $359,000
Q4 2023

Jan 31, 2024

BUY
$222.59 - $267.94 $6,009 - $7,234
27 Added 1.64%
1,674 $433,000
Q3 2023

Oct 25, 2023

BUY
$253.3 - $285.89 $28,369 - $32,019
112 Added 7.3%
1,647 $423,000
Q2 2023

Jul 28, 2023

SELL
$275.25 - $318.06 $17,065 - $19,719
-62 Reduced 3.88%
1,535 $437,000
Q1 2023

Apr 24, 2023

SELL
$256.56 - $292.34 $12,571 - $14,324
-49 Reduced 2.98%
1,597 $444,000
Q4 2022

Jan 20, 2023

SELL
$252.44 - $306.72 $214,826 - $261,018
-851 Reduced 34.08%
1,646 $0
Q3 2022

Nov 15, 2022

SELL
$194.69 - $268.46 $124,990 - $172,351
-642 Reduced 20.45%
2,497 $667,000
Q2 2022

Aug 08, 2022

SELL
$187.54 - $223.02 $48,947 - $58,208
-261 Reduced 7.68%
3,139 $640,000
Q1 2022

May 02, 2022

BUY
$193.77 - $244.14 $30,421 - $38,329
157 Added 4.84%
3,400 $716,000
Q4 2021

Jan 26, 2022

BUY
$223.92 - $287.77 $55,532 - $71,366
248 Added 8.28%
3,243 $778,000
Q3 2021

Nov 12, 2021

SELL
$282.99 - $369.05 $6,791 - $8,857
-24 Reduced 0.79%
2,995 $848,000
Q2 2021

Aug 06, 2021

SELL
$259.0 - $414.71 $229,215 - $367,018
-885 Reduced 22.67%
3,019 $1.05 Million
Q1 2021

May 11, 2021

BUY
$242.95 - $284.63 $26,238 - $30,740
108 Added 2.85%
3,904 $1.09 Million
Q4 2020

Feb 12, 2021

SELL
$236.26 - $355.63 $84,344 - $126,959
-357 Reduced 8.6%
3,796 $929,000
Q3 2020

Nov 09, 2020

BUY
$264.77 - $305.71 $284,627 - $328,638
1,075 Added 34.93%
4,153 $1.18 Million
Q2 2020

Aug 11, 2020

BUY
$258.66 - $342.55 $87,168 - $115,439
337 Added 12.29%
3,078 $824,000
Q1 2020

May 13, 2020

BUY
$268.85 - $341.04 $146,792 - $186,207
546 Added 24.87%
2,741 $867,000
Q4 2019

Feb 03, 2020

SELL
$220.06 - $304.07 $18,044 - $24,933
-82 Reduced 3.6%
2,195 $651,000
Q3 2019

Mar 06, 2020

BUY
$217.44 - $243.88 $4,348 - $4,877
20 Added 0.89%
2,277 $530,000
Q2 2019

Mar 02, 2020

BUY
$219.29 - $241.72 $3,070 - $3,384
14 Added 0.62%
2,257 $528,000
Q1 2019

Mar 02, 2020

SELL
$216.71 - $338.96 $49,843 - $77,960
-230 Reduced 9.3%
2,243 $530,000
Q4 2018

Feb 25, 2020

BUY
$278.5 - $352.75 $1,392 - $1,763
5 Added 0.2%
2,473 $744,000
Q3 2018

Feb 25, 2020

SELL
$293.51 - $383.83 $32,286 - $42,221
-110 Reduced 4.27%
2,468 $872,000
Q1 2018

Jan 30, 2020

BUY
$260.13 - $367.91 $20,030 - $28,329
77 Added 3.08%
2,578 $706,000
Q4 2017

Jan 30, 2020

BUY
$307.64 - $344.58 $769,407 - $861,794
2,501
2,501 $797,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Verdence Capital Advisors LLC Portfolio

Follow Verdence Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verdence Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verdence Capital Advisors LLC with notifications on news.